Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 3/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | ATR | Q13535 | 3/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6514165 | 0.82 | CHEK1 (0.39) | CHEK1CNR2KMT2ATDP1CYP4F2 | |
| SCHEMBL6511094 | 0.80 | CHEK1 (0.41) | CHEK1CNR2KMT2AATMTDP1 | |
| SCHEMBL6511866 | 0.79 | CHEK1 (0.38) | RETCHEK1CNR2KMT2ATDP1 | |
| SCHEMBL6522000 | 0.78 | CHEK1 (0.41) | CHEK1CNR2KMT2AATMTDP1 | |
| SCHEMBL6516690 | 0.77 | CHEK1 (0.42) | CHEK1CNR2KMT2AATMTDP1 | |
| SCHEMBL6515427 | 0.77 | ALDH1A1 (0.41) | CHEK1CNR2KMT2A | |
| SCHEMBL6515376 | 0.75 | MAPT (0.41) | CHEK1CNR2KMT2ATDP1 | |
| SCHEMBL6522817 | 0.75 | CHEK1 (0.39) | CHEK1CNR2KMT2A | |
| SCHEMBL6508753 | 0.74 | CHEK1 (0.47) | IDH1CHEK1KMT2A | |
| SCHEMBL6510843 | 0.72 | CHEK1 (0.47) | IDH1CHEK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | IDH1 3267/4885RET 1690/4885CHEK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.